In vitro antimicrobial activity of a new ophthalmic solution containing hexamidine diisethionate 0.05% (Keratosept)
Antonio Pinna 1 2, Matthew Gavino Donadu 3, Donatella Usai 3, Stefano Dore 1 2, Francesco Boscia 1 2, Stefania Zanetti 3
- 1Ophthalmology Unit, Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy.
- 2Azienda Ospedaliero-Universitaria di Sassari, Sassari, Italy; and.
- 3Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
Abstract
Purpose: To assess the in vitro antimicrobial activity of a new commercial ophthalmic solution containing hexamidine diisethionate 0.05% (Keratosept).
Methods: Staphylococcus aureus American Type Culture Collection (ATCC 43300), Pseudomonas aeruginosa ATCC 27853, 3 ocular bacterial isolates (1 Staphylococcus epidermidis, 1 S. aureus, and 1 P. aeruginosa), and 5 Candida species were used. The bacterial and fungal isolates were cultured on Columbia blood agar base and Sabouraud-dextrose agar plates, respectively, and incubated overnight at 37°C. Suspensions were prepared in a sterile saline solution with optical density equal to 0.5 McFarland standard (∼10 CFU/mL). Isolate suspensions were made in Keratosept solution to obtain a concentration of 10 CFU/mL. The suspensions were then distributed in conical tubes with a final volume of 1 mL and incubated at 37°C. After 1, 5, 10, 15, 20, 25, 30 minutes, and 24 hours, 10 μL of each suspension was removed, seeded on Columbia blood agar base and Sabouraud-dextrose agar plates and then incubated for 24 hours at 37°C.
Results: After 1-minute incubation, there was no growth on the plates seeded with S. aureus ATCC 43300, S. aureus clinical isolate, S. epidermidis clinical isolate, and all 5 Candida species tested. Conversely, Keratosept solution failed to kill the Pseudomonas isolates after 30 minutes exposure and needed 24 hours to eradicate the organisms.
Conclusions: Keratosept ophthalmic solution showed in vitro antimicrobial activity against S. epidermidis, S. aureus, and Candida species. Results suggest that it may be a potential candidate for the treatment of staphylococcal and Candida infections of the ocular surface and have some role in antimicrobial prophylaxis before intravitreal injections.
Pinna, A., Donadu, M. G., Usai, D., Dore, S., Boscia, F., & Zanetti, S. (2020). In vitro antimicrobial activity of a new ophthalmic solution containing hexamidine diisethionate 0.05% (keratosept). Cornea, 39(11), 1415-1418. DOI: 10.1097/ICO.0000000000002375 PMID: 32452982
https://pubmed.ncbi.nlm.nih.gov/32452982/
The contents of this article are directly related to the action of KERATOSEPT® eye drops — learn more here.
